ArticleHNO2025
[Medialization thyroplasty with the VOIS implant : Voice outcomes and experiences].
Article in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adjustable Vocal Implant System (VOIS) for Unilateral Vocal Fold Paralysis: Short-Term Outcomes From a 12-Patient Case Series.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnilateral vocal fold paralysis (UVFP) often leads to considerable limitations in voice quality and voice-related quality of life. Medialization thyroplasty (MT) is an established procedure for voice rehabilitation in cases of glottic insufficiency. Since December 2019, the APrevent® Vocal Implant System (VOIS, APrevent Biotech, Vienna, Austria) has been available in Germany as the first secondarily adjustable implant.
methodsA retrospective evaluation included 12 patients who received MT with the VOIS implant. Voice quality was analyzed multidimensionally at timepoints T0 (preoperative), T1 (2-3 months postoperatively), and T2 (6 months postoperatively).
resultsSignificant improvements were observed in all examined parameters. The mean maximum phonation time (MPT) increased from 5.79 s (T0) to 10.07 s at T1 (p < 0.001) and to 13.22 s at T2 (p = 0.001). Maximum sound pressure level (SPLmax) increased from 77.08 to 86.09 dB at T1 (p = 0.004) and to 86.17 dB at T2 (p = 0.005). Perceptual voice quality, particularly breathiness, improved significantly from 2.29 to 0.73 at T1 (p = 0.004) and to 0.67 at T2 (p = 0.002). Additionally, there was a reduction in the VHI-12 score from 30.73 preoperatively to 11.29 at T1 (p = 0.016) and to 15.22 at T2 (p = 0.008). No significant changes were noted between T1 and T2.
conclusionMedialization thyroplasty with the VOIS implant resulted in significant improvements in voice quality and voice-related quality of life. The unique feature of the VOIS system, i.e., its secondary adjustability without a second surgery, offers potential for further optimization. Further studies are needed on the value of volume correction and the differential indications between MT and reinnervation techniques in UVFP.
Indexed as
Identifiers
40394403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.